Aqueous-humor biomarkers and real-world efficacy of conbercept for diabetic macular edema: a prospective study in elderly patients
- PMID: 40692595
- PMCID: PMC12277135
- DOI: 10.3389/fendo.2025.1632878
Aqueous-humor biomarkers and real-world efficacy of conbercept for diabetic macular edema: a prospective study in elderly patients
Abstract
Background: To evaluate real-world efficacy of conbercept and the predictive value of aqueous-humor biomarkers in elderly diabetic macular edema (DME).
Methods: In this single-arm, prospective study, 150 patients ≥ 65 years received three monthly conbercept injections followed by pro-re-nata dosing over 6 months. Baseline vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) levels were quantified from aqueous humor; best-corrected visual acuity (BCVA) and central subfield thickness (CST) were monitored. Mixed-effects modelling and receiver-operating-characteristic (ROC) analysis explored associations between biomarkers and outcomes.
Results: Mean BCVA improved by approximately nine ETDRS letters, and CST declined by about 85 µm at Month 6. Higher baseline VEGF and IL-6 were associated with greater CST reduction and moderately increased odds of a ≥ 15-letter gain; VEGF showed fair discriminative ability (AUC=0.74). Treatment was well-tolerated, with no unexpected ocular or systemic adverse events.
Conclusion: Conbercept produced meaningful anatomical and functional benefits in an elderly DME cohort. Baseline aqueous VEGF and IL-6, while not definitive stand-alone tests, may help identify eyes likely to achieve pronounced anatomical improvement and warrant further investigation as components of a multi-marker predictive panel.
Keywords: IL-6; VEGF; aqueous humor biomarkers; conbercept; diabetic macular edema; elderly.
Copyright © 2025 Xie.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- Holekamp NM. Overview of diabetic macular edema. Am J managed Care. (2016) 22:s284–91., PMID: - PubMed
-
- Hirashima T, Hagihara M, Oh H. Diabetic Macular Edema. Springer: Cham; (2017) p. 115–27. doi: 10.1007/978-3-319-49840-9_12 - DOI
-
- Okonkwo ON, Akanbi T, Agweye CT. Current management of diabetic macular edema. IntechOpen. (2022). doi: 10.5772/intechopen.100157 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical